J. Joyce and J. Pollard, Microenvironmental regulation of metastasis, Nature Reviews Cancer, vol.19, issue.4, p.239, 2009.
DOI : 10.1053/sonc.2002.37263

L. Mansi, E. Viel, E. Curtit, J. Medioni, L. Tourneau et al., Targeting the RAS signalling pathway in cancer]. Bull Cancer (Paris), oct, vol.98, issue.9, pp.1019-1047, 2011.

J. Douillard, K. Oliner, S. Siena, J. Tabernero, R. Burkes et al., Mutations in Colorectal Cancer, New England Journal of Medicine, vol.369, issue.11, pp.1023-1057, 2013.
DOI : 10.1056/NEJMoa1305275

E. Van-cutsem, H. Lenz, C. Köhne, V. Heinemann, S. Tejpar et al., Mutations in Colorectal Cancer, Journal of Clinical Oncology, vol.33, issue.7, pp.692-700, 2015.
DOI : 10.1200/JCO.2014.59.4812

C. Bokemeyer, C. Köhne, F. Ciardiello, H. Lenz, V. Heinemann et al., FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer, European Journal of Cancer, vol.51, issue.10, pp.1243-52, 1990.
DOI : 10.1016/j.ejca.2015.04.007

S. Richman, M. Seymour, P. Chambers, F. Elliott, C. Daly et al., Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial, Journal of Clinical Oncology, vol.27, issue.35, pp.5931-5938, 2009.
DOI : 10.1200/JCO.2009.22.4295

T. Maughan, R. Adams, C. Smith, A. Meade, M. Seymour et al., Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial, The Lancet, vol.377, issue.9783, pp.2103-2117, 2011.
DOI : 10.1016/S0140-6736(11)60613-2

S. Tejpar, I. Celik, M. Schlichting, U. Sartorius, C. Bokemeyer et al., G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab, Journal of Clinical Oncology, vol.30, issue.29, pp.3570-3577, 2012.
DOI : 10.1200/JCO.2012.42.2592

K. Korphaisarn and S. Kopetz, BRAF-Directed Therapy in Metastatic Colorectal Cancer, The Cancer Journal, vol.22, issue.3, pp.175-183, 2016.
DOI : 10.1097/PPO.0000000000000189

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922502/pdf

T. Ahn, D. Jeong, M. Son, H. Jung, S. Park et al., The BRAF mutation is associated with the prognosis in colorectal cancer, Journal of Cancer Research and Clinical Oncology, vol.127, issue.2, pp.1863-71, 2014.
DOI : 10.3748/wjg.v13.i28.3784

C. Cremolini, F. Loupakis, C. Antoniotti, C. Lupi, E. Sensi et al., FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study, The Lancet Oncology, vol.16, issue.13, pp.1306-1321, 2015.
DOI : 10.1016/S1470-2045(15)00122-9

K. Paschos, A. Majeed, and N. Bird, Natural history of hepatic metastases from colorectal cancer - pathobiological pathways with clinical significance, World Journal of Gastroenterology, vol.20, issue.14, pp.3719-3756, 2014.
DOI : 10.3748/wjg.v20.i14.3719

H. Hurwitz, L. Fehrenbacher, J. Hainsworth, W. Heim, J. Berlin et al., Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.23, issue.15, pp.3502-3510, 2005.
DOI : 10.1200/JCO.2005.10.017

R. Adam, A. De-gramont, J. Figueras, N. Kokudo, F. Kunstlinger et al., Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus, Cancer Treatment Reviews, vol.41, issue.9, pp.729-741, 2015.
DOI : 10.1016/j.ctrv.2015.06.006

URL : http://www.cancertreatmentreviews.com/article/S0305737215001280/pdf

E. Van-cutsem, A. Cervantes, R. Adam, A. Sobrero, J. Van-krieken et al., ESMO consensus guidelines for the management of patients with metastatic colorectal cancer, Annals of Oncology, vol.27, issue.8, pp.1386-422, 2016.
DOI : 10.1093/annonc/mdw235

T. Pawlik and M. Choti, Surgical Therapy for Colorectal Metastases to the Liver, Journal of Gastrointestinal Surgery, vol.22, issue.Suppl 4, pp.1057-77, 2007.
DOI : 10.1200/JCO.2004.06.114

B. Nordlinger, H. Sorbye, B. Glimelius, G. Poston, P. Schlag et al., Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial, The Lancet Oncology, vol.14, issue.12, pp.1208-1223, 2013.
DOI : 10.1016/S1470-2045(13)70447-9

B. Nordlinger, H. Sorbye, B. Glimelius, G. Poston, P. Schlag et al., Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial, The Lancet, vol.371, issue.9617, pp.1007-1023, 2008.
DOI : 10.1016/S0140-6736(08)60455-9

B. Nordlinger, R. Adam, D. Arnold, J. Zalcberg, and T. Gruenberger, The Role of Biological Agents in the Resection of Colorectal Liver Metastases, Clinical Oncology, vol.24, issue.6, pp.432-474, 2012.
DOI : 10.1016/j.clon.2012.01.002

R. Adam, D. Haller, G. Poston, R. J. Spano, J. Tabernero et al., Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer--an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009, Annals of Oncology, vol.21, issue.8, pp.1579-84, 2009.
DOI : 10.1093/annonc/mdq043

URL : https://hal.archives-ouvertes.fr/hal-00741712

M. Ychou, M. Rivoire, S. Thezenas, F. Quenet, J. Delpero et al., A Randomized Phase II Trial of Three Intensified Chemotherapy Regimens in First-Line Treatment of Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases. The METHEP Trial, Annals of Surgical Oncology, vol.16, issue.13, pp.4289-97, 2013.
DOI : 10.1634/theoncologist.2011-0141

R. Adam, V. Delvart, G. Pascal, A. Valeanu, D. Castaing et al., Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy, Transactions of the ... Meeting of the American Surgical Association, vol.CXXII, issue.&NA;, pp.644-657, 2004.
DOI : 10.1097/01.sla.0000141198.92114.f6

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1356466/pdf

S. Benoist, A. Brouquet, C. Penna, C. Julié, E. Hajjam et al., Complete Response of Colorectal Liver Metastases After Chemotherapy: Does It Mean Cure?, Journal of Clinical Oncology, vol.24, issue.24, pp.3939-3984, 2006.
DOI : 10.1200/JCO.2006.05.8727

G. Mentha, S. Terraz, P. Morel, A. Andres, E. Giostra et al., Dangerous halo after neoadjuvant chemotherapy and two-step hepatectomy for colorectal liver metastases, British Journal of Surgery, vol.34, issue.1, pp.95-103, 2009.
DOI : 10.1016/j.ejso.2007.09.016

E. Van-cutsem, C. Köhne, E. Hitre, J. Zaluski, C. Chien et al., Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.360, issue.14, pp.1408-1425, 2009.
DOI : 10.1056/NEJMoa0805019

C. Bokemeyer, I. Bondarenko, A. Makhson, J. Hartmann, J. Aparicio et al., Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.27, issue.5, pp.663-71, 2009.
DOI : 10.1200/JCO.2008.20.8397

G. Folprecht, T. Gruenberger, W. Bechstein, H. Raab, J. Weitz et al., Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)???, Annals of Oncology, vol.25, issue.5, pp.1018-1043, 2014.
DOI : 10.1093/annonc/mdu088

T. Gruenberger, J. Bridgewater, I. Chau, G. Alfonso, P. Rivoire et al., Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial, Annals of Oncology, vol.26, issue.4, pp.702-710, 2015.
DOI : 10.1093/annonc/mdu580

L. Ye, T. Liu, L. Ren, Y. Wei, D. Zhu et al., Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liverlimited metastases, J Clin Oncol Off J Am Soc Clin Oncol. 1 juin, vol.31, issue.16, 2013.

R. Wong, D. Cunningham, Y. Barbachano, C. Saffery, J. Valle et al., A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection, Annals of Oncology, vol.22, issue.9, pp.2042-2050, 2011.
DOI : 10.1093/annonc/mdq714

D. Blazer, Y. Kishi, D. Maru, S. Kopetz, Y. Chun et al., Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases, Journal of Clinical Oncology, vol.26, issue.33, pp.5344-51, 2008.
DOI : 10.1200/JCO.2008.17.5299

R. Adam, D. Wicherts, R. De-haas, O. Ciacio, F. Lévi et al., Patients With Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure?, Journal of Clinical Oncology, vol.27, issue.11, pp.1829-1864, 2009.
DOI : 10.1200/JCO.2008.19.9273

R. Adam, D. Wicherts, R. De-haas, T. Aloia, F. Lévi et al., Complete Pathologic Response After Preoperative Chemotherapy for Colorectal Liver Metastases: Myth or Reality?, Journal of Clinical Oncology, vol.26, issue.10, pp.1635-1676, 2008.
DOI : 10.1200/JCO.2007.13.7471

S. Benoist and B. Nordlinger, The Role of Preoperative Chemotherapy in Patients with Resectable Colorectal Liver Metastases, Annals of Surgical Oncology, vol.23, issue.18S, pp.2385-90, 2009.
DOI : 10.1038/bjc.1998.333

D. Goèré, S. Gaujoux, F. Deschamp, F. Dumont, A. Souadka et al., Patients Operated On for Initially Unresectable Colorectal Liver Metastases With Missing Metastases Experience a Favorable Long-Term Outcome, Annals of Surgery, vol.254, issue.1, pp.114-122, 2011.
DOI : 10.1097/SLA.0b013e31821ad704

S. Gaujoux, D. Goéré, F. Dumont, A. Souadka, C. Dromain et al., Complete Radiological Response of Colorectal Liver Metastases after Chemotherapy: What Can We Expect?, Digestive Surgery, vol.28, issue.2, pp.114-134, 2011.
DOI : 10.1159/000323820

R. Auer, R. White, N. Kemeny, L. Schwartz, J. Shia et al., Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy, Cancer, vol.16, issue.6, pp.1502-1511, 2010.
DOI : 10.1002/cncr.24912

K. Tanaka, H. Takakura, K. Takeda, K. Matsuo, Y. Nagano et al., Importance of Complete Pathologic Response to Prehepatectomy Chemotherapy in Treating Colorectal Cancer Metastases, Annals of Surgery, vol.250, issue.6
DOI : 10.1097/SLA.0b013e3181b0c6e4

D. Elias, D. Goere, V. Boige, N. Kohneh-sharhi, D. Malka et al., Outcome of Posthepatectomy-Missing Colorectal Liver Metastases after Complete Response to Chemotherapy: Impact of Adjuvant Intra-arterial Hepatic Oxaliplatin, Annals of Surgical Oncology, vol.24, issue.1, pp.3188-94, 2007.
DOI : 10.1245/s10434-007-9482-9

R. Adam, R. De-haas, D. Wicherts, T. Aloia, V. Delvart et al., Is Hepatic Resection Justified After Chemotherapy in Patients With Colorectal Liver Metastases and Lymph Node Involvement?, Journal of Clinical Oncology, vol.26, issue.22, pp.3672-80, 2008.
DOI : 10.1200/JCO.2007.15.7297

L. Rubbia-brandt, E. Giostra, C. Brezault, A. Roth, A. Andres et al., Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery, Annals of Oncology, vol.18, issue.2, pp.299-304, 2007.
DOI : 10.1093/annonc/mdl386

J. Vauthey, T. Pawlik, D. Ribero, T. Wu, D. Zorzi et al., Chemotherapy Regimen Predicts Steatohepatitis and an Increase in 90-Day Mortality After Surgery for Hepatic Colorectal Metastases, Journal of Clinical Oncology, vol.24, issue.13, pp.2065-72, 2006.
DOI : 10.1200/JCO.2005.05.3074

D. Ribero, H. Wang, M. Donadon, D. Zorzi, M. Thomas et al., Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases, Cancer, vol.27, issue.12, pp.2761-2768, 2007.
DOI : 10.1038/sj.bmt.1703061

G. Morris-stiff, Y. Tan, and J. Vauthey, Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases, European Journal of Surgical Oncology (EJSO), vol.34, issue.6, pp.609-623, 2008.
DOI : 10.1016/j.ejso.2007.07.007

O. Soubrane, A. Brouquet, S. Zalinski, B. Terris, C. Brézault et al., Predicting High Grade Lesions of Sinusoidal Obstruction Syndrome Related to Oxaliplatin-Based Chemotherapy for Colorectal Liver Metastases, Annals of Surgery, vol.251, issue.3, pp.454-60, 2010.
DOI : 10.1097/SLA.0b013e3181c79403

I. Kamel, M. Choti, K. Horton, H. Braga, B. Birnbaum et al., Surgically Staged Focal Liver Lesions: Accuracy and Reproducibility of Dual-Phase Helical CT for Detection and Characterization, Radiology, vol.227, issue.3, pp.752-759, 2003.
DOI : 10.1148/radiol.2273011768

M. Yang, D. Martin, N. Karabulut, and M. Frick, Comparison of MR and PET imaging for the evaluation of liver metastases, Journal of Magnetic Resonance Imaging, vol.177, issue.3, pp.343-352, 2003.
DOI : 10.1002/jmri.10265

B. Wiering, P. Krabbe, G. Jager, W. Oyen, and T. Ruers, The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases, Cancer, vol.233, issue.12, pp.2658-70, 2005.
DOI : 10.1097/00000658-200103000-00001

N. Lubezky, U. Metser, R. Geva, R. Nakache, E. Shmueli et al., The Role and Limitations of 18-Fluoro-2-deoxy-d-glucose Positron Emission Tomography (FDG-PET) Scan and Computerized Tomography (CT) in Restaging Patients with Hepatic Colorectal Metastases Following Neoadjuvant Chemotherapy: Comparison with Operative and Pathological Findings, Journal of Gastrointestinal Surgery, vol.182, issue.Suppl 2, pp.472-480, 2007.
DOI : 10.2214/ajr.182.1.1820092

T. Ruers, B. Wiering, J. Van-der-sijp, R. Roumen, K. De-jong et al., Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study, J Nucl Med Off Publ Soc Nucl Med. juill, vol.50, issue.7, pp.1036-1077, 2009.

E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-275, 1990.
DOI : 10.1016/j.ejca.2008.10.026

Y. Chun, J. Vauthey, P. Boonsirikamchai, D. Maru, S. Kopetz et al., Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases, JAMA, vol.302, issue.21, pp.2338-2382, 2009.
DOI : 10.1001/jama.2009.1755

B. Fioole, R. De-haas, D. Wicherts, S. Elias, J. Scheffers et al., Additional value of contrast enhanced intraoperative ultrasound for colorectal liver metastases, European Journal of Radiology, vol.67, issue.1, pp.169-76, 2008.
DOI : 10.1016/j.ejrad.2007.03.017

E. Leen, P. Ceccotti, S. Moug, P. Glen, J. Macquarrie et al., Potential Value of Contrast-Enhanced Intraoperative Ultrasonography During Partial Hepatectomy for Metastases, Annals of Surgery, vol.243, issue.2, pp.236-276, 2006.
DOI : 10.1097/01.sla.0000197708.77063.07

M. Chirica, M. Leconte, O. Oberlin, and B. Dousset, [Surgical treatment of liver metastasis in patients with colorectal cancer]. Presse Medicale Paris Fr 1983, janv, vol.41, issue.1, pp.58-67, 2012.

Y. Fong, J. Fortner, R. Sun, M. Brennan, and L. Blumgart, Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer, Annals of Surgery, vol.230, issue.3, pp.309-318, 1999.
DOI : 10.1097/00000658-199909000-00004

R. De-haas, D. Wicherts, E. Flores, D. Azoulay, D. Castaing et al., R1 Resection by Necessity for Colorectal Liver Metastases, Transactions of the ... Meeting of the American Surgical Association, vol.126, pp.269-80, 2008.
DOI : 10.1097/SLA.0b013e31818a07f1

S. Truant, O. Oberlin, G. Sergent, G. Lebuffe, L. Gambiez et al., Remnant Liver Volume to Body Weight Ratio ???0.5%: A New Cut-Off to Estimate Postoperative Risks after Extended Resection in Noncirrhotic Liver, Journal of the American College of Surgeons, vol.204, issue.1, pp.22-33, 2007.
DOI : 10.1016/j.jamcollsurg.2006.09.007

B. Nordlinger, J. Vaillant, M. Guiguet, P. Balladur, F. Paris et al., Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie., Journal of Clinical Oncology, vol.12, issue.7, pp.1491-1497, 1994.
DOI : 10.1200/JCO.1994.12.7.1491

P. Allen, N. Kemeny, W. Jarnagin, R. Dematteo, L. Blumgart et al., Importance of Response to Neoadjuvant Chemotherapy in Patients Undergoing Resection of Synchronous Colorectal Liver Metastases, Journal of Gastrointestinal Surgery, vol.7, issue.1, pp.109-115, 2003.
DOI : 10.1016/S1091-255X(02)00121-X

G. Mentha, P. Majno, A. Andres, L. Rubbia-brandt, P. Morel et al., Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary, British Journal of Surgery, vol.231, issue.7, pp.872-880, 2006.
DOI : 10.1002/bjs.5346

S. Zalinski, C. Mariette, and O. Farges, Prise en charge des patients atteints de m??tastases h??patiques synchrones du cancer colorectal. Recommandations pour la Pratique Clinique. Recommandations de la Soci??t?? fran??aise de chirurgie digestive (SFCD) et de l???association de chirurgie hepatobiliaire et de transplantation h??patique (ACHBT). Texte court, Journal de Chirurgie Visc??rale, vol.148, issue.3, pp.196-208, 2011.
DOI : 10.1016/j.jchirv.2011.05.008

A. Andres, C. Toso, R. Adam, E. Barroso, C. Hubert et al., A Survival Analysis of the Liver-First Reversed Management of Advanced Simultaneous Colorectal Liver Metastases, Annals of Surgery, vol.256, issue.5, pp.772-778, 2012.
DOI : 10.1097/SLA.0b013e3182734423

A. Brouquet, M. Mortenson, J. Vauthey, M. Rodriguez-bigas, M. Overman et al., Surgical Strategies for Synchronous Colorectal Liver Metastases in 156 Consecutive Patients: Classic, Combined or Reverse Strategy?, Journal of the American College of Surgeons, vol.210, issue.6, pp.934-975, 2010.
DOI : 10.1016/j.jamcollsurg.2010.02.039

A. Van-der-pool, J. De-wilt, Z. Lalmahomed, A. Eggermont, J. Ijzermans et al., Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases, British Journal of Surgery, vol.11, issue.3, pp.383-90, 2010.
DOI : 10.3748/wjg.v13.i9.1431

S. Mayo, C. Pulitano, H. Marques, J. Lamelas, C. Wolfgang et al., Surgical Management of Patients with Synchronous Colorectal Liver Metastasis: A Multicenter International Analysis, Journal of the American College of Surgeons, vol.216, issue.4, pp.707-716, 2013.
DOI : 10.1016/j.jamcollsurg.2012.12.029

P. Lykoudis, O. Reilly, D. Nastos, K. Fusai, and G. , Systematic review of surgical management of synchronous colorectal liver metastases, British Journal of Surgery, vol.15, issue.6, pp.605-617, 2014.
DOI : 10.1111/j.1477-2574.2012.00597.x

M. Kelly, G. Spolverato, G. Lê, M. Mavros, F. Doyle et al., Synchronous colorectal liver metastasis: A network meta-analysis review comparing classical, combined, and liver-first surgical strategies, Journal of Surgical Oncology, vol.90, issue.3, pp.341-51, 2015.
DOI : 10.1002/bjs.4132

R. Adam, A. Laurent, D. Azoulay, D. Castaing, and H. Bismuth, Two-Stage Hepatectomy: A Planned Strategy to Treat Irresectable Liver Tumors, Annals of Surgery, vol.232, issue.6, pp.777-85, 2000.
DOI : 10.1097/00000658-200012000-00006

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1421270/pdf

A. Dupré, M. Hitier, P. Peyrat, Y. Chen, P. Meeus et al., Associating portal embolization and artery ligation to induce rapid liver regeneration in staged hepatectomy, British Journal of Surgery, vol.15, issue.12, pp.1541-50, 2015.
DOI : 10.1111/j.1477-2574.2012.00607.x

S. Tsai, H. Marques, M. De-jong, M. P. Ribeiro, V. Choti et al., Two-stage strategy for patients with extensive bilateral colorectal liver metastases, HPB, vol.12, issue.4, pp.262-271, 2010.
DOI : 10.1111/j.1477-2574.2010.00161.x

URL : https://doi.org/10.1111/j.1477-2574.2010.00161.x

M. Narita, E. Oussoultzoglou, D. Jaeck, P. Fuchschuber, E. Rosso et al., Two-stage hepatectomy for multiple bilobar colorectal liver metastases, British Journal of Surgery, vol.138, issue.10, pp.1463-75, 2011.
DOI : 10.1016/j.jss.2006.07.027

D. Goéré, O. Farges, J. Leporrier, A. Sauvanet, V. Vilgrain et al., Chemotherapy Does Not Impair Hypertrophy of the Left Liver After Right Portal Vein Obstruction, Journal of Gastrointestinal Surgery, vol.10, issue.3, pp.365-70, 2006.
DOI : 10.1016/j.gassur.2005.09.001

S. Togo, Y. Nagano, H. Masui, K. Tanaka, Y. Miura et al., Two-stage hepatectomy for multiple bilobular liver metastases from colorectal cancer, Hepatogastroenterology. juin, vol.52, issue.63, pp.913-922, 2005.

A. Schnitzbauer, S. Lang, H. Goessmann, S. Nadalin, J. Baumgart et al., Right Portal Vein Ligation Combined With In Situ Splitting Induces Rapid Left Lateral Liver Lobe Hypertrophy Enabling 2-Staged Extended Right Hepatic Resection in Small-for-Size Settings, Annals of Surgery, vol.255, issue.3, pp.405-419, 2012.
DOI : 10.1097/SLA.0b013e31824856f5

E. Schadde, D. Raptis, A. Schnitzbauer, V. Ardiles, C. Tschuor et al., Prediction of Mortality After ALPPS Stage-1, Annals of Surgery, vol.262, issue.5, pp.780-785, 2015.
DOI : 10.1097/SLA.0000000000001450

T. Ruers, C. Punt, F. Van-coevorden, J. Pierie, I. Borel-rinkes et al., Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a??randomized EORTC Intergroup phase II study (EORTC 40004), Annals of Oncology, vol.23, issue.10, pp.2619-2645, 2012.
DOI : 10.1093/annonc/mds053

C. Compton, D. Byrd, J. Garcia-aguilar, S. Kurtzman, A. Olawaiye et al., AJCC Cancer Staging Atlas [Internet], Disponible sur, pp.978-979, 2017.

M. Tsai, Y. Su, M. Ho, J. Liang, T. Chen et al., Clinicopathological Features and Prognosis in Resectable Synchronous and Metachronous Colorectal Liver Metastasis, Annals of Surgical Oncology, vol.119, issue.2, pp.786-94, 2007.
DOI : 10.1148/radiology.218.1.r01dc1155

A. Van-der-pool, Z. Lalmahomed, Y. Ozbay, J. De-wilt, A. Eggermont et al., ???Staged??? liver resection in synchronous and metachronous colorectal hepatic metastases: differences in clinicopathological features and outcome, Colorectal Disease, vol.25, issue.10Online, pp.229-235, 2010.
DOI : 10.1200/JCO.2007.11.0833

K. Sasaki, G. Margonis, N. Andreatos, A. Wilson, M. Weiss et al., Prognostic impact of margin status in liver resections for colorectal metastases after bevacizumab, British Journal of Surgery, vol.302, issue.7, pp.926-961, 2017.
DOI : 10.1001/jama.2009.1755

L. Mekenkamp, M. Koopman, S. Teerenstra, J. Van-krieken, L. Mol et al., Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases, British Journal of Cancer, vol.10, issue.2, pp.159-64, 2010.
DOI : 10.1038/sj.bjc.6604093

M. Bockhorn, A. Frilling, N. Frühauf, J. Neuhaus, E. Molmenti et al., Survival of Patients with Synchronous and Metachronous Colorectal Liver Metastases???is there a Difference?, Journal of Gastrointestinal Surgery, vol.15, issue.Suppl 4, pp.1399-405, 2008.
DOI : 10.1097/01.RVI.0000159543.28222.73

Y. Wang, Z. Wang, F. Wang, Y. Yuan, B. Li et al., The Role of Adjuvant Chemotherapy for Colorectal Liver Metastasectomy after Pre-Operative Chemotherapy: Is the Treatment Worthwhile?, Journal of Cancer, vol.8, issue.7, pp.1179-86, 2017.
DOI : 10.7150/jca.18091

Q. Lin, Q. Ye, D. Zhu, Y. Wei, L. Ren et al., Determinants of Long-Term Outcome in Patients Undergoing Simultaneous Resection of Synchronous Colorectal Liver Metastases, PLoS ONE, vol.20, issue.8, p.105747, 2014.
DOI : 10.1371/journal.pone.0105747.t003

Y. Mise, T. Aloia, K. Brudvik, L. Schwarz, J. Vauthey et al., Parenchymal-sparing Hepatectomy in Colorectal Liver Metastasis Improves Salvageability and Survival, Annals of Surgery, vol.263, issue.1, pp.146-52, 2016.
DOI : 10.1097/SLA.0000000000001194

G. Van-der-wal, A. Gouw, J. Kamps, H. Moorlag, M. Bulthuis et al., Angiogenesis in Synchronous and Metachronous Colorectal Liver Metastases, Annals of Surgery, vol.255, issue.1, pp.86-94, 2012.
DOI : 10.1097/SLA.0b013e318238346a

A. Slesser, P. Georgiou, G. Brown, S. Mudan, R. Goldin et al., The tumour biology of synchronous and metachronous colorectal liver metastases: a systematic review, Clinical & Experimental Metastasis, vol.17, issue.24, pp.457-70, 2013.
DOI : 10.1158/1078-0432.CCR-10-2816

L. Wang and J. Gu, Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis, Cancer Epidemiology, vol.36, issue.1, pp.61-68, 2012.
DOI : 10.1016/j.canep.2011.05.002